COPD patients who did not receive triple therapy promptly after their index exacerbation had a greater comorbidity burden than patients with prompt initiation of triple therapy, found the latest research by a team of researchers at University of Illinois College of Pharmacy, University of Wisconsin-Madison School of Pharmacy and Medical University of South Carolina. The study established that patients with delayed or very delayed triple therapy also showed evidence of more severe disease, such as greater use of maintenance treatments, including rescue medications, and more frequent pulmonologist visits in the year before their index exacerbation. The retrospective observational study included 24,770 patients equal to or older than 40 years with COPD who initiated triple therapy after severe exacerbations in the prior year.